Opens in a new tab or window Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia ...

The voluntary model, led by the Center for Medicare and Medicaid Innovation, aims to test outcomes-based agreements for cell and gene therapies. CMS says that the model will increase access for ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

So far, this has limited access to these therapies, particularly in older or resource poor groups eligible for Medicare or Medicaid in the US. The Cell and Gene Therapy Access Model, run by the ...

CMS will launch the new payment model in January 2025. Individual states may also choose to participate in the arrangement and need to signify their intent to do so between January 2025 and January ...

Epistasis describes how gene interactions can affect phenotypes. Did you know that genes can mask each other's presence or combine to produce an entirely new trait? But what happens when two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Disorders like muscular dystrophies are difficult to treat using gene therapies because of a ... to normal levels in two different animal models of muscular dystrophy. Specifically, StitchR ...

Company and CMMI agreed to key terms to be offered to State Medicaid Agencies to support access to LYFGENIA™ gene therapy for sickle cell disease States can opt in to an outcomes-based agreement with ...